Hoth Therapeutics, Inc. (NASDAQ:HOTH) Short Interest Update

Hoth Therapeutics, Inc. (NASDAQ:HOTH) saw a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 633,400 shares, a growth of 117.4% from the December 15th total of 291,300 shares. Currently, 9.3% of the company’s shares are short sold. Based on an average daily volume of 8,650,000 shares, the days-to-cover ratio is currently 0.1 days.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on HOTH shares. HC Wainwright reiterated a “buy” rating and issued a $4.00 price objective on shares of Hoth Therapeutics in a research report on Monday, November 4th. D. Boral Capital reiterated a “buy” rating and issued a $5.00 price target on shares of Hoth Therapeutics in a report on Tuesday, January 7th. Finally, Benchmark restated a “speculative buy” rating and issued a $3.00 price objective on shares of Hoth Therapeutics in a report on Friday, October 11th.

Hoth Therapeutics Trading Up 4.6 %

HOTH traded up $0.07 during trading on Thursday, reaching $1.58. The stock had a trading volume of 1,167,896 shares, compared to its average volume of 50,086,957. Hoth Therapeutics has a one year low of $0.58 and a one year high of $3.80. The company has a market capitalization of $10.90 million, a price-to-earnings ratio of -1.20 and a beta of 0.75. The stock’s 50 day moving average is $0.97 and its two-hundred day moving average is $0.89.

Hoth Therapeutics (NASDAQ:HOTH) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.01). On average, equities research analysts predict that Hoth Therapeutics will post -1.18 earnings per share for the current year.

Institutional Trading of Hoth Therapeutics

A hedge fund recently bought a new stake in Hoth Therapeutics stock. Virtu Financial LLC bought a new position in Hoth Therapeutics, Inc. (NASDAQ:HOTH) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned approximately 0.47% of Hoth Therapeutics at the end of the most recent quarter. Institutional investors own 7.08% of the company’s stock.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.